TABLE 1.
Clinical characteristics of the patient cohort included in this study. Adapted from Ref. 7
| Patients, n = 60 | |
|---|---|
| Male, n (%) | 40 (67) |
| Age, median (range) | 57.5 (32–91) |
| Body mass index (kg/m2), median (range) | 30 (22–45) |
| Cardiovascular disease, a n (%) | 33 (55) |
| Chronic pulmonary disease, n (%) | 15 (25) |
| Chronic renal failure, n (%) | 7 (12) |
| Current or ex‐smoker, n (%) | 33 (55) |
| Diabetes, n (%) | 15 (25) |
| Immunocompromised b at inclusion, n (%) | 8 (13) |
| Symptom duration at inclusion, days median (range) | 10 (2–30) |
| COVID‐19 severity | |
| Mild, n (%) | 6 (10) |
| Moderate, n (%) | 25 (42) |
| Severe, n (%) | 21 (35) |
| Critical, n (%) | 8 (13) |
a
Includes hypertension.
b
Disease and/or on current immunosuppressant medicine, such as haematological or other malignancies, organ transplantation and rheumatic disease.